Navigation Links
Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript
Date:6/6/2013

PHILADELPHIA and REHOVOT, Israel, June 6, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a manuscript reporting data validating the clinical utility of the Rosetta Cancer Origin Test (formerly miRview® mets2) to identify the tumor of origin in Cancer of Unknown or Uncertain Primary (CUP) has been accepted for publication in the peer-reviewed on-line journal Molecular Cancer. The article, titled "Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary," represents the seventh peer-reviewed publication relating to our CUP assays, and the fifth peer-reviewed publication relating to post market validation studies demonstrating the Cancer Origin Test's ability to identify tumor origin in CUP with 92% concordance, the highest level of accuracy of any similar study published to date.

The manuscript discusses the performance of the Cancer Origin Test, an assay utilizing 64 microRNAs to identify 42 tumor types, in formalin-fixed paraffin-embedded (FFPE) samples from 84 CUP patients The results showed concordance with the final diagnosis in 92% of patients; representing an improvement in agreement of 22 percentage points from presentation diagnosis to final diagnosis, which final diagnosis was  achieved after more precise clinical and pathological data was added to the data relied upon for the patient's initial assessment.

"MicroRNAs are particularly well-suited as biomarkers for identifying tumor origin as their expression levels and profile reflects tissue origin.  Importantly, microRNAs have been shown to be highly stable in tissue block
'/>"/>

SOURCE Rosetta Genomics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
2. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
3. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
4. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
5. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
6. Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories
7. Rosetta Genomics Announces Presence at ASCO 2013
8. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
9. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
10. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
11. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... 30, 2015 According to a ... Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, ... Clinical Trial), by End Users - Global Forecast to ... to reach USD 2,107.99 million by 2020 from USD ... Browse more than 75 ...
(Date:7/30/2015)... 2015  With over 60,000 customers across the globe, ISN improves the efficiency and ... with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers ... Headquartered in Dallas, TX , ISN has ...
(Date:7/30/2015)... York, NY (PRWEB) , ... July 30, 2015 , ... As part of its 2015 ... raw material and technical service business units, Whitehouse Laboratories is pleased to ... will be adjacent to the Container Center of Excellence and will be strictly dedicated to ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... Nov. 7 Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) ... Biotech Boston Confab on Tuesday, November,11th at 9:40 a.m. ... presentation can be accessed under,"Calendar of Events" in the ... approximately 5-10 minutes before the,event to ensure a timely ...
... Changes Treatment ... Clinical Practice -, REDWOOD CITY, Calif., Nov. 10 ... of results from a study,indicating that Oncotype DX(R) Recurrence Score(R) ... published in the,October issue of the American Journal of Surgery, ...
... patients with complex lesions, NATICK, Mass., Nov. ... today announced that it has received approval from,the ... Apex(TM) PTCA(1),Dilatation Catheter. The Apex Catheter is a ... needs in,treating the most challenging atherosclerotic lesions. It ...
Cached Biology Technology:Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 2Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 3Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 4FDA Approves Boston Scientific's Apex(TM) PTCA Dilatation Catheter 2FDA Approves Boston Scientific's Apex(TM) PTCA Dilatation Catheter 3FDA Approves Boston Scientific's Apex(TM) PTCA Dilatation Catheter 4
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... caused more than $193 million in hospital-based medical care ... problems such as asthma and pneumonia that are triggered ... Corporation study. Researchers estimate that exposure to excessive ... emergency room visits and hospital admissions over the study ...
... paper that describes a file format used by scientists ... citations in the ISI Web of Knowledge, an online ... The Systems Biology Markup Language (SBML) is designed to ... between different computer software packages, allowing the models to ...
... In one of the most comprehensive global studies of marine ... University of Rhode Island and other institutions has found that ... success of marine reserves. "We make a big mistake ... and other aquatic organisms," said Richard Pollnac, URI professor of ...
Cached Biology News:Study finds dirty air in California causes millions worth of medical care each year 2Study finds dirty air in California causes millions worth of medical care each year 3After 5 years, free systems biology markup language has proven popular 2After 5 years, free systems biology markup language has proven popular 3Scientists find community involvement, not only enforcement, drives success of marine reserves 2
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... aqueous solution that contains a purified bovine ... a saline solution, pH 6.5 7.5, ... and 0.02% bromonitrodioxane as a preservative. ... stabilizer for biologically active components in solution, ...
AC input: 230 V...
Biology Products: